Immix Biopharma - A quarter focusing on a CAR-T strategy
Following recent updates regarding Immix’s CAR-T therapy (NXC-201) and Q123 results, we have adjusted our financial estimates. Quarterly R&D...
198 Views
Immix Biopharma - CAR-T treatment continues to show promise
Immix Biopharma continues to share encouraging data from the Phase Ib/II open-label NEXICART-1 trial. This study is investigating NXC-201, a CAR-T...
356 Views
Immix Biopharma - Pipeline momentum continues in FY23
Immix Biopharma’s FY22 results reflected a busy period as management ramped up clinical activity across multiple programs. In a major development,...
434 Views
Immix Biopharma - Positive data from CAR-T treatment continues
Immix Biopharma has announced additional data from the ongoing Phase Ib/II open-label NEXICART-1 trial investigating the company’s CAR-T therapy,...
412 Views
Immix Biopharma - Expanding portfolio into CAR-T cell therapy
Immix Biopharma has expanded both its clinical and technology portfolio with the in-licensing of its first CAR-T cell therapy, NXC-201. The...
415 Views